(Q39223387)

English

miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease

scientific article published on July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

cell differentiation

1 reference

based on heuristic

inferred from title

Michele Caraglia

11

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Antonio Giordano

13

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

object named as

Marco Rossi

1

0 references

object named as

Cirino Botta

7

0 references

Manlio Ferrarini

object named as

Manlio Ferrarini

12

0 references

Pierfrancesco Tassone

15

object named as

Pierfrancesco Tassone

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Pierosandro Tagliaferri

14

object named as

Pierosandro Tagliaferri

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

author name string

Maria Rita Pitari

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Nicola Amodio

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Maria Teresa Di Martino

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Francesco Conforti

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Emanuela Leone

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Francesco Maria Paolino

8

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Teresa Del Giudice

9

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Eleonora Iuliano

10

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

publication date

1 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Journal of Cellular Physiology

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

228

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1506-1515

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

A comparative study of disaggregated chick and rat osteoclasts in vitro: effects of calcitonin and prostaglandins.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

MicroRNAs: genomics, biogenesis, mechanism, and function

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Bisphosphonate infusions: patient preference, safety and clinic use.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

MicroRNAs in Cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

MicroRNA biogenesis and regulation of bone remodeling

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Regulation of type I collagen genes expression

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

RANK ligand inhibition with denosumab for the management of osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

MicroRNAs in the pathobiology of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

MicroRNA as a novel drug target for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Supportive care in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

New insights into osteoclastogenic signaling mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Structure, function, and regulation of tartrate-resistant acid phosphatase

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Molecular mechanisms of action of bisphosphonates.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Molecular targets for the treatment of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Biophosphonate-related osteonecrosis of the jaws

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

The pharmacology of bisphosphonates and new insights into their mechanisms of action

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Suppression of hepatic stellate cell activation by microRNA-29b.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Promises and challenges of MicroRNA-based treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Editorial: New approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta).

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Bortezomib inhibits human osteoclastogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Fos/AP-1 proteins in bone and the immune system

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Bone and haematopoietic defects in mice lacking c-fos

1 reference

https://api.crossref.org/works/10.1002%2FJCP.24306

21 January 2018

Identifiers

10.1002/JCP.24306

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

release_j6rxlkbicfetvmkgumgpqwbfdi

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39223387&oldid=2088767496"